Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.90 |
| ▸ | MEN1 | O00255 | 6/20 | 0.90 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.90 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.90 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.90 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.90 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.90 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.90 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.90 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.90 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.90 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.90 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.90 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.90 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.90 |
| ▸ | LTA4H | P09960 | 1/20 | 0.90 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | THRB | P10828 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29382031 | 1.00 | ALDH1A1 (0.90) | ALDH1A1MEN1KMT2AHDAC8HDAC1 | |
| Scriptaid SCHEMBL29383029 | 0.94 | HDAC8 (1.00) | ALDH1A1MEN1KMT2AHDAC8HDAC1 | |
| Scriptaid SCHEMBL780490 | 0.94 | HDAC8 (1.00) | ALDH1A1MEN1KMT2AHDAC8HDAC1 | |
| SCHEMBL25583412 | 0.87 | MEN1 (0.70) | ALDH1A1MEN1KMT2AHDAC8HDAC1 | |
| SCHEMBL5852563 | 0.85 | HDAC8 (0.83) | ALDH1A1MEN1KMT2AHDAC8HDAC1 | |
| SCHEMBL3134908 | 0.84 | MEN1 (1.00) | ALDH1A1MEN1KMT2AHDAC8HDAC1 | |
| SCHEMBL20258450 | 0.82 | KDM4E (0.84) | ALDH1A1MEN1KMT2AHDAC8HDAC1 | |
| SCHEMBL10323380 | 0.82 | ALDH1A1 (0.79) | ALDH1A1MEN1KMT2AHDAC8HDAC1 | |
| SCHEMBL25583414 | 0.82 | KDM4E (0.69) | ALDH1A1MEN1KMT2AHDAC8HDAC1 | |
| SCHEMBL19513510 | 0.81 | HDAC1 (0.76) | ALDH1A1MEN1KMT2AHDAC8HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 358 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4508211-A2 | THERAPEUTIC APPLICATIONS OF CRISPR TYPE V SYSTEMS | Caribou Biosciences, Inc. (US) | 2025-02-19 | — | — | EP | claimed |
| CN-118974253-A | Therapeutic application of CRISPR V-type system | 卡里布生物科学公司 | 2024-11-15 | — | — | CN | claimed |
| WO-2023201270-A2 | THERAPEUTIC APPLICATIONS OF CRISPR TYPE V SYSTEMS | CARIBOU BIOSCIENCES, INC. (US) | 2023-10-19 | — | — | WO | claimed |
| WO-2008141189-A1 | GHRELIN MODULATING COMPOUNDS AND COMBINATIONS THEREOF | ELIXIR PHARMACEUTICALS, INC. (US) | 2008-11-20 | — | — | WO | claimed |
| US-20060148684-A1 | Use of a histone deacetylase inhibitor for treating muscular dystrophies | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS (FR) | 2006-07-06 | — | — | US | claimed |
| US-6544957-B2 | Methods and reagents for facilitating transcription | THE JOHNS HOPKINS UNIVERSITY | 2003-04-08 | — | — | US | claimed |
| US-20010031722-A1 | Methods and reagents for facilitating transcription | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2001-10-18 | — | — | US | claimed |
| US-20260078414-A1 | Materials and Methods for Treatment of Pain Related Disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-03-19 | — | — | US | disclosed |
| EP-3481857-B1 | MATERIALS AND METHODS FOR TREATMENT OF PAIN RELATED DISORDERS | VERTEX PHARMA (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20260015582-A1 | METHODS OF T CELL DIFFERENTIATION AND COMPOSITIONS THEREOF | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2026-01-15 | — | — | US | disclosed |
| US-12492388-B2 | Materials and methods for treatment of hemoglobinopathies | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-12-09 | — | — | US | disclosed |
| EP-4652262-A1 | USE OF REGENERATION FACTORS IN ORGAN TRANSPLANTATION | Altos Labs, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4650364-A2 | MATERIALS AND METHODS FOR TREATMENT OF PAIN RELATED DISORDERS | Vertex Pharmaceuticals Incorporated (US) | 2025-11-19 | — | — | EP | disclosed |
| EP-1861126-A2 | TREATMENT OF PROTEIN DEGRADATION DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-12-05 | — | — | EP | disclosed |
| US-20060239909-A1 | Treatment of protein degradation disorders | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2006-10-26 | — | — | US | disclosed |
| WO-2006102557-A2 | TREATMENT OF PROTEIN DEGRADATION DISORDERS | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006102557-A2 | TREATMENT OF PROTEIN DEGRADATION DISORDERS | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2006-09-28 | — | — | WO | disclosed |
| US-20060148684-A1 | Use of a histone deacetylase inhibitor for treating muscular dystrophies | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS (FR) | 2006-07-06 | — | — | US | disclosed |
| US-6544957-B2 | Methods and reagents for facilitating transcription | THE JOHNS HOPKINS UNIVERSITY | 2003-04-08 | — | — | US | disclosed |
| US-20010031722-A1 | Methods and reagents for facilitating transcription | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2001-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015582-A1 | METHODS OF T CELL DIFFERENTIATION AND COMPOSITIONS THEREOF | CD4, CD47, CD63 | ALDH1A1 4165/4885MEN1 2018/4885KMT2A 1767/4885 |
| US-20060239909-A1 | Treatment of protein degradation disorders | HDAC6, HDAC5, AADAC | ALDH1A1 3847/4885MEN1 3426/4885KMT2A 156/4885 |
| US-20260078414-A1 | Materials and Methods for Treatment of Pain Related Disorders | SCN9A, SCN7A, SCN8A | ALDH1A1 1780/4885MEN1 3506/4885KMT2A 1132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.